|Articles|November 2, 2022
Veeva and Merck Announce Partnership
Ten-year partnership will help Merck reduce operational costs and deliver value to patients, HCPs.
Advertisement
Veeva announced a ten-year strategic partnership agreement with Merck that builds on the existing 12-year partnership between the companies. Under the terms of the agreement, Merck will select Veeva products when they are fit for purpose. Veeva will provide Merck with a strategic pricing approach and Merck will have input into Veeva's product roadmap.
Read more about the partnership
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Generative AI Transforms Clinical Study Report DevelopmentSeptember 16th 2025
Operational Strategies That Strengthened the NIMBLE Trial DesignSeptember 16th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Merck Reports Strong Phase II Results for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer
2
Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome
3
ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research
4
Atom Therapeutics Launches Global Phase II Trial of Novel Anti-Inflammatory Treatment for Acute Gout Flares
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
